Krypton Laser Photocoagulation for Neovascular Lesions of Age-Related Macular Degeneration

Gold nanoparticle enhancement of stereotactic radiosurgery for neovascular age-related macular degeneration

“…On the other hand, the highly localized nature of the dose enhancement suggests that a treatment plan could be tailored such that targeted neovascular AMD EC are boosted to higher doses beyond the 24 Gy while still maintaining normal tissue dose limits achieved without AuNP. Previous studies have indicated that better vision outcomes may be secured with radiation treatment at higher doses (Fine and Maguire 2001).…”

“…To this end, a non-invasive, kilovoltage stereotactic radiosurgery (SRS) system has recently been developed and commercialized for the treatment of neovascular AMD (Oraya Therapeutics Inc., Newark, CA) (Petrarca and Jackson 2011, Hanlon et al 2009, Moshfeghi et al 2011b. The rationale for such a radiotherapy approach is based on evidence that the rapidly proliferating neovascular endothelial cells (EC) that drive AMD development are relatively more radiosensitive than quiescent or less actively dividing cells (Fine andMaguire 2001, Bonnaud et al 2007). The Oraya radiotherapy system can accurately deliver radiation dose of up to 24 Gy to the radiosensitive choroidal neovasculature during a single treatment session, while maintaining dose limits to neighboring organs at risk (Hanlon et al 2009, Hanlon et al 2011.…”

Gold nanoparticle enhancement of stereotactic radiosurgery for neovascular age-related macular degeneration

“…On the other hand, the highly localized nature of the dose enhancement suggests that a treatment plan could be tailored such that targeted neovascular AMD EC are boosted to higher doses beyond the 24 Gy while still maintaining normal tissue dose limits achieved without AuNP. Previous studies have indicated that better vision outcomes may be secured with radiation treatment at higher doses (Fine and Maguire 2001).…”

“…To this end, a non-invasive, kilovoltage stereotactic radiosurgery (SRS) system has recently been developed and commercialized for the treatment of neovascular AMD (Oraya Therapeutics Inc., Newark, CA) (Petrarca and Jackson 2011, Hanlon et al 2009, Moshfeghi et al 2011b. The rationale for such a radiotherapy approach is based on evidence that the rapidly proliferating neovascular endothelial cells (EC) that drive AMD development are relatively more radiosensitive than quiescent or less actively dividing cells (Fine andMaguire 2001, Bonnaud et al 2007). The Oraya radiotherapy system can accurately deliver radiation dose of up to 24 Gy to the radiosensitive choroidal neovasculature during a single treatment session, while maintaining dose limits to neighboring organs at risk (Hanlon et al 2009, Hanlon et al 2011.…”

Gold nanoparticle enhancement of stereotactic radiosurgery for neovascular age-related macular degeneration

“…On the other hand, the highly localized nature of the dose enhancement suggests that a treatment plan could be tailored such that targeted neovascular AMD EC are boosted to higher doses beyond the 24 Gy while still maintaining normal tissue dose limits achieved without AuNP. Previous studies have indicated that better vision outcomes may be secured with radiation treatment at higher doses (Fine and Maguire 2001).…”

“…To this end, a non-invasive, kilovoltage stereotactic radiosurgery (SRS) system has recently been developed and commercialized for the treatment of neovascular AMD (Oraya Therapeutics Inc., Newark, CA) (Petrarca and Jackson 2011, Hanlon et al 2009, Moshfeghi et al 2011b. The rationale for such a radiotherapy approach is based on evidence that the rapidly proliferating neovascular endothelial cells (EC) that drive AMD development are relatively more radiosensitive than quiescent or less actively dividing cells (Fine andMaguire 2001, Bonnaud et al 2007). The Oraya radiotherapy system can accurately deliver radiation dose of up to 24 Gy to the radiosensitive choroidal neovasculature during a single treatment session, while maintaining dose limits to neighboring organs at risk (Hanlon et al 2009, Hanlon et al 2011.…”

Gold nanoparticle enhancement of stereotactic radiosurgery for neovascular age-related macular degeneration

“…On the other hand, the highly localized nature of the dose enhancement suggests that a treatment plan could be tailored such that targeted neovascular AMD EC are boosted to higher doses beyond the 24 Gy while still maintaining normal tissue dose limits achieved without AuNP. Previous studies have indicated that better vision outcomes may be secured with radiation treatment at higher doses (Fine and Maguire 2001).…”

“…To this end, a non-invasive, kilovoltage stereotactic radiosurgery (SRS) system has recently been developed and commercialized for the treatment of neovascular AMD (Oraya Therapeutics Inc., Newark, CA) (Petrarca and Jackson 2011, Hanlon et al 2009, Moshfeghi et al 2011b. The rationale for such a radiotherapy approach is based on evidence that the rapidly proliferating neovascular endothelial cells (EC) that drive AMD development are relatively more radiosensitive than quiescent or less actively dividing cells (Fine andMaguire 2001, Bonnaud et al 2007). The Oraya radiotherapy system can accurately deliver radiation dose of up to 24 Gy to the radiosensitive choroidal neovasculature during a single treatment session, while maintaining dose limits to neighboring organs at risk (Hanlon et al 2009, Hanlon et al 2011.…”